MJ Acquisition Indigestion Hits Bottom Line, But Bio-Rad Hungry for More M&A | GenomeWeb

Despite suffering from bottom-line indigestion relating to the acquisition of MJ GeneWorks in August, Bio-Rad Laboratories has negotiated a $200 million line of credit to go after even more acquisitions, the company said in a conference call last week after the release of its fourth-quarter financials.

In the quarter, which ended Dec. 31, the company sold $200 million of 6.125-percent senior subordinated notes due 2014 in a private offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.